Ownership history in NATIXIS · 10 quarters on record
This page tracks every 13F SEC filing in which NATIXIS reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 73,342 | +73,322 | +366610.0% | 0.02% | $3.8M | $51.94 |
| 2025 Q2 | REDUCED | 20 | -18,480 | -99.9% | 0.00% | $864 | $43.18 |
| 2024 Q4 | UNCHANGED | 18,500 | — | 0% | 0.00% | $508K | $27.44 |
| 2024 Q3 | REDUCED | 18,500 | -13,300 | -41.8% | 0.00% | $471K | $25.46 |
| 2023 Q3 | ADDED | 31,800 | +25,800 | +430.0% | 0.01% | $839K | $26.37 |
| 2023 Q2 | REDUCED | 6,000 | -9,000 | -60.0% | 0.00% | $103K | $17.20 |
| 2023 Q1 | REDUCED | 15,000 | -14,375 | -48.9% | 0.00% | $249K | $16.58 |
| 2021 Q3 | ADDED | 29,375 | +23,725 | +419.9% | 0.00% | $1.4M | $46.87 |
| 2021 Q2 | ADDED | 5,650 | +1,250 | +28.4% | 0.00% | $344K | $60.96 |
| 2021 Q1 | INITIATED | 4,400 | — | — | 0.00% | $271K | $61.60 |
As of 2025 Q4 — sorted by position size